Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 14/20 | 0.82 |
| ▸ | RANBP1 | P43487 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16322954 | 1.00 | XPO1 (0.82) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17790542 | 1.00 | XPO1 (0.82) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL23133403 | 0.93 | XPO1 (0.71) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17788772 | 0.93 | XPO1 (0.71) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL23133420 | 0.93 | XPO1 (0.71) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17788771 | 0.93 | XPO1 (0.71) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17788770 | 0.93 | XPO1 (0.71) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL23116715 | 0.92 | XPO1 (0.70) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL23116700 | 0.92 | XPO1 (0.70) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL29666379 | 0.92 | XPO1 (0.70) | XPO1RANBP1KCNH2ESR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945794-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4306517-A1 | TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shenzhen Jikang Pharmaceutical Technology Co., Ltd. (CN) | 2024-01-17 | — | — | EP | disclosed |
| EP-3492455-B1 | 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND USE IN THE TREATMENT OF SPECIFIC FORMS OF CANCER | KARYOPHARM THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20220177445-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2022-06-09 | — | — | US | disclosed |
| US-11124493-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200199099-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2020-06-25 | — | — | US | disclosed |
| US-10407405-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3492455-A1 | 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND USE IN THE TREATMENT OF SPECIFIC FORMS OF CANCER | Karyopharm Therapeutics Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3010892-B1 | 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180155317-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2018-06-07 | — | — | US | disclosed |
| US-9738624-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738624-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160152596-A1 | Nuclear Transport Modulators and Uses Thereof | Karyopharm Therapeutics Inc. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152596-A1 | Nuclear Transport Modulators and Uses Thereof | Karyopharm Therapeutics Inc. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3010892-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014205389-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177445-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
| US-11945794-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
| US-20180155317-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
| US-10407405-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
| US-11124493-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
| US-20160152596-A1 | Nuclear Transport Modulators and Uses Thereof | XPO5, XPO1, XPOT | XPO1 2/4885RANBP1 144/4885KCNH2 4320/4885 |
| US-20200199099-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.